Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Day One Biopharmaceuticals (DAWN) EBITDA Margin (2024 - 2025)

Historic EBITDA Margin for Day One Biopharmaceuticals (DAWN) over the last 2 years, with Q3 2025 value amounting to 60.94%.

  • Day One Biopharmaceuticals' EBITDA Margin fell 925500.0% to 60.94% in Q3 2025 from the same period last year, while for Sep 2025 it was 123.9%, marking a year-over-year increase of 835000.0%. This contributed to the annual value of 165.65% for FY2024, which is N/A changed from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported EBITDA Margin of 60.94% as of Q3 2025, which was down 925500.0% from 103.14% recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' EBITDA Margin registered a high of 31.61% during Q3 2024, and its lowest value of 1401.45% during Q2 2024.